Jean-François Obadia, ESC 2019 – Follow up from the MITRA-FR Trial
We spoke to Professor Jean-François Obadia (Civils Hospices of Lyon, Lyon, France) about the 2-year follow up from the MITRA-FR trial, and how he would interpret the differing results from recent studies into the efficacy of the MitraClip in patients with mitral regurgitation. Finally, he touches on which patients might be likely to benefit from the intervention and how physicians can best identify them.
Speaker’s Disclosures: Jean-François Obadia has received research grants from Abbott and the French Ministry of Health and is a consultant for Dealcroix-Chevalier, Lanadanger, Medtronic, SJM (Abbott), Novartis and Sorin.
1. What update can you provide from the 2-year follow up of the MITRA-FR trial? (0:05)
2. How would you interpret the differing results between recent studies into the efficacy of MitraClip in patients with mitral regurgitation? (1:00)
3. How can physicians identify patients most likely to benefit from this intervention? (1:44)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.
Share this Video
Related Videos In Hypertension
Kelly Chin, ACC 2023: The treatment paradigm for patients with pulmonary arterial hypertension
Recommended therapy for patients with pulmonary arterial hypertension is generally a combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the treatment paradigm. Dr Chin presented an abstract entitled ‘Efficacy And Safety Of […]
Kelly Chin, ACC 2023: A DUE phase III study, a macitentan and tadalafil combination for patients with pulmonary arterial hypertension
The aim of the A DUE study was to assess the combination of macitentan and tadalafil for patients with pulmonary arterial hypertension. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the findings of the trial and the clinical impact. The abstract entitled ‘Efficacy And […]
Marius Hoeper, ACC 2023: STELLAR phase III trial results – Sotatercept for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease involving proliferative remodeling of the pulmonary vessels and elevations in pulmonary vascular resistance (PVR). Despite recent treatment advances, the associated morbidity and mortality rates of the disease are still high. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!